Press Releases

Jul 10, 2024 7:30 am EDT Kazia Therapeutics Announces Phase II/III Clinical Trial Results for Paxalisib in Glioblastoma

Jun 27, 2024 8:15 am EDT KAZIA ANNOUNCES UPCOMING DIPG DATA PRESENTATIONS AT ISPNO AND PUBLICATION IN EUROPEAN JOURNAL OF CANCER

May 23, 2024 2:41 pm EDT Kazia Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement

May 1, 2024 8:45 am EDT KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS

Mar 21, 2024 8:52 am EDT Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases

Mar 13, 2024 8:00 am EDT Kazia announces presentation of new data at AACR Annual Meeting

Feb 21, 2024 7:30 am EST Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint

Jan 18, 2024 7:30 am EST KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

Dec 5, 2023 6:02 pm EST Kazia Therapeutics Announces Closing of $2 Million Registered Direct Offering

Dec 1, 2023 8:00 am EST Kazia Therapeutics Announces $2 Million Registered Direct Offering